No Data
No Data
Tus-Pharmaceutical Group: 2024 Interim Performance Forecast
Tus-Pharmaceutical Group (000590.SZ): Expected loss of 210-270 million yuan in the first half of the year, turning profit to loss year-on-year.
On July 10th, Gelonhui reported that Tus-Pharmaceutical Group (000590.SZ) released a performance forecast for the first half of 2024, with a net loss of 21 million yuan to 27 million yuan attributable to shareholders of listed companies during the reporting period, compared with a profit of 6.3825 million yuan in the same period last year. After deducting non-recurring gains and losses, the net loss was 22 million yuan to 28 million yuan, compared with a profit of 3.5492 million yuan in the same period last year. The basic loss per share was between 0.0877 yuan/share and 0.1127 yuan/share. The main reason for the net profit loss attributable to shareholders of listed companies in the first half of 2024 is the changes in medical insurance and pharmaceutical policies during the reporting period.
Tus-Pharmaceutical Group Co., Ltd. (SZSE:000590) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Enlightenment Pharmaceutical (000590.SZ): Hengyang State-owned Assets Administration Commission plans to transfer 5.84% of the shares to Hongxiang Group free of charge
Gelonghui, May 7, 丨 Enlightenment Pharmaceutical (000590.SZ) announced that it recently received the “Notice on the Free Transfer of Enlightenment Pharmaceutical Shares” from the Hengyang Municipal People's Government State-owned Assets Supervision and Administration Committee (“Hengyang State-owned Assets Administration Commission”), the third largest shareholder. The main content of the notice is that the Hengyang Municipal State-owned Assets Administration Commission decided to transfer the 13,988,705 shares of the Company with unlimited sales conditions (5.84% of the company's total share capital) to Hengyang Hongxiang State-owned Investment (Holdings) Group Co., Ltd. (“Hongxiang Group”) free of charge. After the implementation of this free transfer of state-owned shares is completed, Hongxiang Group will maintain
Enlightenment Pharmaceutical (000590.SZ) announced first-quarter results with a net loss of 8.2843 million yuan
Enlightenment Pharmaceutical (000590.SZ) released its report for the first quarter of 2024, achieving 770 operating income during the reporting period...
Additional Considerations Required While Assessing Tus-Pharmaceutical Group's (SZSE:000590) Strong Earnings
No Data